Udai Banerji
@udaibanerji.bsky.social
📤 64
📥 13
📝 19
Clinician Scientist, passionate translational medicine and drug discovery in oncology and beyond...
Fuelling the qest for the next generation of clinician scientists. Great opportunity!
add a skeleton here at some point
about 2 months ago
0
1
0
PhD convocation ceremony at
@icr.ac.uk
with DrDr Alvaro Graces. His thesis entitled Clonal Dynamics and evolutionary pathways in high grade serous ovarian cancer under therapeutic pressure siggests our current use of chemotherapy can be better optimised.
@trevorgraham.bsky.social
2 months ago
0
2
1
Interesting insights into phase I trial recruitment in oncology and health care utilization using data extracted from unstructured text in health care records.
pubmed.ncbi.nlm.nih.gov/40855012/
@icr.ac.uk
@royalmarsden.org
@ecmc-uk.bsky.social
@crukconvergence.bsky.social
@nihr.bsky.social
4 months ago
0
3
0
Organoid culture is prohibitively expensive. Solution to Harvest Organoids Efficiently (SHOE) allows rapid and inexpensive harvesting of organoids. Please use in your research labs and cite.
pubmed.ncbi.nlm.nih.gov/40641211/
@icr.ac.uk
@royalmarsden.org
@crukconvergence.bsky.social
6 months ago
0
4
0
Antibody-drug-conjugate toxicity is real and poorly understood. Looking for trends in association with antibody/linker/payloads.
pubmed.ncbi.nlm.nih.gov/40611310/
@icr.ac.uk
@royalmarsden.org
@ecmc-uk.bsky.social
@crukconvergence.bsky.social
6 months ago
0
6
0
Published today
@natmed.nature.com
www.nature.com/articles/s41...
Thank you to all patients, families and research staff.
@icr.ac.uk
@icrdduiit.bsky.social
@icr-ctsu.bsky.social
@royalmarsden.org
@ecmc-uk.bsky.social
@nihr.bsky.social
@crukconvergence.bsky.social
@cancerresearchuk.org
6 months ago
0
4
1
Published today in
@natmed.nature.com
www.nature.com/articles/s41...
combination of avutometinib and defactinib in LGSOC.
@icr.ac.uk
@icrdduiit.bsky.social
@icr-ctsu.bsky.social
@royalmarsden.org
@ecmc-uk.bsky.social
@nihr.bsky.social
@crukconvergence.bsky.social
@cancerresearchuk.org
6 months ago
0
2
1
#MCCR2025
. Methods in clinical cancer research workshop hits its 25 year birthday! Fabulous opportunity to train young oncologists to develop research protocols. Especially proud to have been a trainee over 20 years ago and having served as faculty. @ESMO @EORTC
@theaacr.bsky.social
7 months ago
0
2
0
Sharing good practice to run complex radio-immuno conjugate trials in the UK to accelerate drug development and improve outcomes of cancer patients.
@ecmc.bsky.social
@icr.ac.uk
@icrdduiit.bsky.social
@nihr.bsky.social
@cruk.bsky.social
8 months ago
0
1
0
Professor Paul Workman, fellow of AACR, talking on the urgency in developing chemical probes to fight cancer.
#AACR2025
@icr.ac.uk
8 months ago
0
1
0
End of a long day at AACR. Presented using patient derived organoids to understand and refine mechanisms of synergy of avutometinib and defactinb combination in low grade ovarian, an area of unmet need.
@icr.ac.uk
@crukconvergence.bsky.social
@nihr.bsky.social
@ecmc-uk.bsky.social
8 months ago
0
1
2
Masterclass in next generation ADCs! ED11
#AACR2025
worth watching online if you missed it.
8 months ago
0
1
0
Only at
#AACR
2025, Love the commitment!!!
8 months ago
1
2
0
#AACR2025
has begun. Educational sessions on plasticity/drug resistance and models of cancer evolution. Feel the buzz!
@icr.ac.uk
@cancerresearchuk.org
@nihr.bsky.social
8 months ago
0
3
0
Happy retirement to my wife Jane, joined nurse training 42 years ago, worked across several NHS trusts and Australian public hospitals on clinical trials of carboplatin, VP16 (etoposide), GCSF, ondansetron and CHART RT in clinic. Worked in tral management @icr since 2005. Time to put up your feet!
10 months ago
0
3
0
www.icr.ac.uk/about-us/icr...
Blog about projects
@icrlondon.bsky.social
in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…
11 months ago
0
5
5
Unfolded protein response meets AR transcription. We need to think out the box to tackle known oncogenic drivers. Great piece of work from my colleague @AdamSharpMedOnc out this week
aacrjournals.org/clincancerre...
@icrlondon.bsky.social
@theaacr.bsky.social
loading . . .
NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth
Abstract. Purpose: Advanced prostate cancer (PCa) is invariably fatal with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men w...
https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-24-2386/750830/NXP800-activates-the-unfolded-protein-response
12 months ago
0
3
0
Very interesting personalized m-RNA cancer vaccine paper in nature medicine
www.nature.com/articles/s41...
published this week establishing proof concept of the technology. Trial was led by my colleague Juantia Lopez and our unit was involved as part of an international clinical trial.
loading . . .
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial - Nature Medicine
In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in comb...
https://www.nature.com/articles/s41591-024-03334-7
12 months ago
0
6
1
you reached the end!!
feeds!
log in